Veradermics, Inc

Co Veradermics, Inc zaraportowała 11 sierpnia 2026

Z własnego raportu 8-K spółki.

Konferencje wynikowe

Dla spółki Veradermics, Inc brak dostępnego zapisu konferencji wynikowej.

Co powiedział zarząd

“In the second quarter of 2026, we made significant advancements in the development of VDPHL01 for female pattern hair loss, supporting key milestones for the program. The positive Phase 2 results from Study ‘207’ marked the first successful clinical demonstration of an oral treatment for female pattern hair loss in the United States and increased our conviction in VDPHL01 as a potential treatment for women as we advance toward registration-directed topline data from the now fully enrolled Phase 2/3 Study ‘306’ in the first half of 2027,”

Cytowane dosłownie z komunikatu i pokazywane tylko wtedy, gdy raport przypisuje wypowiedź konkretnej osobie.

Jak zareagował kurs

Komunikaty pojawiają się po zamknięciu albo przed otwarciem, więc ruch dotyczy kolejnej sesji.

Czym zajmuje się Veradermics, Inc

VDPHL01 (extended-release minoxidil tablet) is a proprietary investigational, oral non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. VDPHL01 leverages extended-release technology to deliver a minoxidil product with the potential for improved efficacy and safety. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption. VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow. If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern Exhibit 99.1 hair loss in both male and female patients. VDPHL01 is protected by a broad library of patents and patent applications related to the key innovations of VDPHL01. The earliest expiring patent term is 2043.

Własny opis spółki, tak jak widnieje na końcu komunikatu.